<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853875</url>
  </required_header>
  <id_info>
    <org_study_id>21MMHIS016e</org_study_id>
    <nct_id>NCT04853875</nct_id>
  </id_info>
  <brief_title>ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin</brief_title>
  <official_title>Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mackay Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori (H. pylori) is a spiral shaped, microaerophilic, gram negative bacterium.&#xD;
      The organism resides in the acid and mucous layer of the human gastric mucosa, adheres to and&#xD;
      colonizes the mucosal surface of the stomach and the mucosal epithelium with gastric&#xD;
      metaplasia of duodenal bulb. Many studies have shown that H. pylori is an important causal&#xD;
      factor of chronic gastritis, peptic ulcer disease, gastric cancer and gastric lymphoma.&#xD;
      Endoscopic examination is indicated to confirm the above diagnosis for patient with H. pylori&#xD;
      infection. The eradication rate of standard triple therapy has fallen below 80% in many&#xD;
      countries due to the worldwide increasing prevalence of antibiotic resistant strains. This is&#xD;
      related to the special gastric milieu of H. pylori, which leads to a more difficult and&#xD;
      complicated treatment for achieving a successful eradication rate than other bacteria.&#xD;
      Several strategies have been proposed to increase the eradication rate in the first line&#xD;
      therapy or as a rescue therapy. However, these rescue therapies will increase the side&#xD;
      effects and costs of treatment, decrease the compliance of patients and increase the rate of&#xD;
      worldwide antibiotic resistance steadily. The WHO has listed H. Pylori as one of 12&#xD;
      antibiotic-resistant bacteria that have the greatest threat to human health in Feb. 2017. Our&#xD;
      previous studies suggested that the administration of single -dose therapeutic agents can&#xD;
      achieve the eradication of H. pylori immediately while conducting the endoscopic examination.&#xD;
      The eradication rate of intraluminal therapy for H. pylori infection (ILTHPI) is 53.7%&#xD;
      (51/95), and control the intragastric pH above 4 prior to the ILTHPI can even reach a&#xD;
      72.0%(36/50) eradication rate of H. pylori.&#xD;
&#xD;
      According to the recent Taiwan consensus for the treatment of H. pylori in 2017, the first&#xD;
      line therapeutic regiment of H. pylori containing Amoxicillin, Clarithromycin, and&#xD;
      Metronidazole if the rate of Clarithromycin resistance is below 15%, while the first line&#xD;
      therapeutic regiment of H. pylori containing tetracycline, metronidazole, and bismuth&#xD;
      subcitrate if the rate of Clarithromycin resistance is above 15%. We aimed to evaluate and&#xD;
      compare the efficacy of medicament containing Tetracycline, Metronidazole, and Bismuth versus&#xD;
      Amoxicillin, Metronidazole, and Clarithromycin for the Intraluminal therapy of Helicobacter&#xD;
      pylori infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the endoscopic examination, patient is sedated with intravenous Midazolam 5mg and&#xD;
      Fentanyl 0.05mg, the vital signs will be closely monitored by physiological monitor (PHILIPS&#xD;
      SureSigns VM6). The treatment will be terminated immediately if unstable vital sign detected&#xD;
      or if patient asks for termination. The pH value of gastric juice will be measured with the&#xD;
      pH test strips. and the he gastric mucus is irrigated with acetylcysteine solution. The&#xD;
      investigators randomly assigned medicaments containing different antibiotic powders either&#xD;
      Tetracycline 2g, Metronidazole 2g, and Bismuth 480mg (Group A) or Amoxicillin 3g,&#xD;
      Metronidazole 2g, and Clarithromycin 1g (Group B) to dispense on the surface of gastric&#xD;
      mucosa and duodenal mucosa of duodenal bulb. After the intraluminal therapy, patients will&#xD;
      rest for 30 to 60 minutes and go home if the effect of sedation subsided. Patients can take&#xD;
      meal if no abdominal discomfort. C13-Urea breath test (UBT) will be used to assess the&#xD;
      existence of H. pylori 2 weeks after the intraluminal therapy. Patients failed to achieve&#xD;
      intraluminal eradication of H. pylori will be assigned to 7-day concomitant therapy (Group A)&#xD;
      or 7-day bismuth quadruple therapy (Group B). The C13-UBT will be used to assess the&#xD;
      existence of H. pylori 4 weeks after the oral antibiotic therapy. The overall eradication&#xD;
      rates of the intraluminal therapy plus the oral antibiotics therapies will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>104 participants are randomly assigned to receive intraluminal eradication of H. pylori.&#xD;
with medicaments containing Tetracycline, Metronidazole, and Bismuth versus Amoxicillin, Metronidazole, and Clarithromycin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The eradication rates of intraluminal therapy</measure>
    <time_frame>C13-UBT will be used to assess the existence of H. pylori 2 weeks after the intraluminal therapy</time_frame>
    <description>To evaluate and compare the eradication rates of different medicaments for the Intraluminal Therapy for Helicobacter pylori Infection between Group A and Group B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The adverse events of intraluminal therapy</measure>
    <time_frame>Within one week after the Intraluminal Therapy for Helicobacter pylori Infection</time_frame>
    <description>of different medicaments for the Intraluminal Therapy for Helicobacter pylori Infection between Group A and Group B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The eradication rates of oral antibiotic rescue therapies</measure>
    <time_frame>C13-UBT will be used to assess the existence of H. pylori 4 weeks after the oral antibiotics rescue therapy</time_frame>
    <description>To evaluate and compare the eradication rates of different oral antibiotic rescue therapies for failed Intraluminal Therapy between concomitant therapy ( Group A) and bismuth-based quadruple therapy (Group B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adverse events of oral antibiotic rescue therapies</measure>
    <time_frame>Within one week after complete the oral antibiotics rescue therapy</time_frame>
    <description>To evaluate and compare the adverse events of different oral antibiotic rescue therapies for failed Intraluminal Therapy between concomitant therapy ( Group A) and bismuth-based quadruple therapy (Group B)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Group A (Tetracycline, Metronidazole, and Bismuth)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Tetracycline 2g, Metronidazole 2g, and Bismuth subcitrate 480 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Amoxicillin, Metronidazole, and Clarithromycin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Amoxicillin 3g, Metronidazole 2g, and Clarithromycin 1g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline, Metronidazole, Bismuth subcitrate</intervention_name>
    <description>52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate</description>
    <arm_group_label>Group A (Tetracycline, Metronidazole, and Bismuth)</arm_group_label>
    <other_name>Bismuth Trioxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin, Metronidazole, Clarithromycin</intervention_name>
    <description>52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin</description>
    <arm_group_label>Group B (Amoxicillin, Metronidazole, and Clarithromycin)</arm_group_label>
    <other_name>Klaricid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged between 20 years and 75 years&#xD;
&#xD;
          2. Patients have H. pylori infection and have not treated with oral antibiotics&#xD;
&#xD;
          3. Patients are willing to receive the intraluminal therapy. The written informed&#xD;
             consents will be obtained from all patients prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if any one of the following criteria is&#xD;
             present:&#xD;
&#xD;
               1. Children and teenagers aged less than 20 years, or adult greater than 75 years&#xD;
&#xD;
               2. Contraindication for endoscopic examination or food retention in the gastric&#xD;
                  lumen&#xD;
&#xD;
               3. History of gastrectomy; Gastroduodenal stenosis„ÄÅdeformity or obstruction;&#xD;
                  Gastroduodenal malignancy, including adenocarcinoma and lymphoma&#xD;
&#xD;
               4. Contraindication to treatment drugs: previous allergic reaction to antibiotics of&#xD;
                  study, PPI (Lansoprazole), Acetylcysteine and Sucralfate; pregnant or lactating&#xD;
                  women&#xD;
&#xD;
               5. Severe concurrent acute or chronic illness: renal failure, decompensated&#xD;
                  cirrhosis of liver, incurable malignant disease&#xD;
&#xD;
               6. Patients who cannot give informed consent by himself or herself&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tai-cherng Liou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tai-cherng Liou, MD</last_name>
    <phone>+886-2-25433535</phone>
    <phone_ext>3993</phone_ext>
    <email>mmhltc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tai-cherng Liou, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mackay Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Tai-cherng Liou, MD</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Metronidazole</keyword>
  <keyword>Bismuth</keyword>
  <keyword>Tetracycline</keyword>
  <keyword>Clarithromycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

